Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of bomedemstat versus best available therapy in hydroxyurea-refractory or -intolerant essential thrombocythemia
CTR20242627Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bomedemstat in thrombocythemia, sponsored by Merck & Co.. Started Nov 2024; status: active.
02
Drugs
bomedemstat
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on CTR20242627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242627.